High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide

The aim of this study is to assess nucleoprotein expression of IKZF1/3 in patients with relapsed/refractory multiple myeloma (MM) who received lenalidomide-based therapy and correlated them with their clinical outcomes. A total of 50 patients diagnosed with MM were entered in the study with the median follow-up of 86.4 months. By immunohistochemistry (IHC), IKZF1 and IKZF3 were expressed in 72 and 58% of the cases, respectively. IKZF1 and IKZF3 expressions were associated with longer median progression free survival (P = 0.0029 and P < 0.0001) and overall survival (P = 0.0014 and P < 0.0001). IKZF3 expression also appears predicted a favorable response to the lenalidomide-based therapy. Electronic supplementary material The online version of this article (doi:10.1186/s13045-016-0354-2) contains supplementary material, which is available to authorized users.

It has been demonstrated that lenalidomide causes selective degradation of IKZF1 (ikaros) and IKZF3 (aiolos) which are two essential transcription factors for myeloma cell proliferation [1,2]. This anti-proliferative effect is mediated by downregulation of c-Myc and interferon regulatory factor 4 (IRF4) [3]. In particular, IKZF3 regulates expression of IRF4 which is linked with lenalidomide activity [4][5][6]. However, the clinical relevance of IKZF1/IKZF3 expressions in myeloma patients has not been established. Thus, we examined nuclear expression of IKZF1/3 and its correlation with clinical outcomes in patients with relapsed/refractory MM who received lenalidomide therapy.
A total of 50 patients diagnosed with MM in our institution were entered in the study. All had received lenalidomide-based therapy (lenalidomide plus dexamethasone) after relapse. The median follow-up after diagnosis was 7.2 years. The relevant clinical and laboratory features are summarized in Table 1. CD138 and IKZF1/3 immunohistochemical (IHC) staining were performed on the bone marrow aspiration/biopsy specimens taken before starting lenalidomide. CD138 positive myeloma cell aggregates (Additional file 1: Figure S1B) were examined for IKZF1/3 expression (Additional file 1: Figure S1C, D). H-score method (range 0-300) according to staining intensity and percentage of myeloma cells was applied. The median Hscores for IKZF1 and IKZF3 were 150 and 200, respectively, and high or low expression was based on above or below the median H-score (Fig. 1a).
Previous studies have indicated controversial results about the relationship between Ikaros expression level and resistance to lenalidomide. Lu et al. [7] found that some MM cell lines with higher expressions of IKZF1 or IKZF3 showed resistance to the drug; in contrast, Zhu et al. [8] showed that low IKZF1 transcript levels were correlated with poor response to IMiDs. They also found that higher IKZF1 but not IKZF3 gene expression was associated with better OS. Our study demonstrates that expression of IKZF1/3 proteins (especially IKZF3) is correlated with better outcome in refractory MM patients treated with lenalidomide. A possible explanation for this observation is that in the presence of high IKZF1/3 levels, myeloma cells are more dependent on IKZF-associated signaling for proliferation.
Particularly, IKZF3 is linked to plasma cell development and lenalidomide efficacy as IKZF3 is specifically required for the generation of long-lived plasma cells and it has been shown to be reduced by lenalidomide [9,10].
To the best of our knowledge, this is the first report to show a correlation between IKZF1/3 protein expressions and clinical outcomes in refractory MM treated with lenalidomide. However, this study has limitations as it is retrospective with limited sample size. Nevertheless, as paraffin IHC is routinely available, robust, and inexpensive, if confirmed in a larger prospective study, IKZF1/3 (especially IKZF3) immunostaining can be readily adopted in clinical practice for prediction of drug response and clinical outcomes in MM patients receiving lenalidomide therapy.

Additional file
Additional file 1: Figure S1. Bone marrow biopsy from a patient with MM. (A) H&E stain, (B) CD138 for myeloma cells, (C) Nuclear expression of IKZF1, (D) Nuclear expression of IKZF3.